What is Theravance Biopharma's SG&A?

Theravance Biopharma (TBPH) reported SG&A of $17.72M in Q1 2026.

How has Theravance Biopharma's SG&A changed year-over-year?

Theravance Biopharma's SG&A decreased by 3.5% year-over-year, from $18.37M to $17.72M.

What is the long-term trend for Theravance Biopharma's SG&A?

Over 4 years (2021 to 2025), Theravance Biopharma's SG&A has grown at a -7.2% compound annual growth rate (CAGR), from $99.3M to $73.65M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Theravance Biopharma TBPH SG&A

SG&A at other companies

Zevra Therapeutics, Inc.ZVRA

$20.78M+6.3%

LQD

Liquidia CorporationLQDA

$46.94M+56.1%

United TherapeuticsUTHR

$184.1M+8.2%

PrecigenPGEN

$21.05M+70.3%

Ultragenyx PharmaceuticalRARE

$88M+1.1%

OrganonOGN

$424M+1.0%

Other financials

Income statement

See full

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Cash flow

See full

Operating cash flow$73.3M+70.3%

CapEx$8.0K-95.8%

Free cash flow$59.6M+5,560%

Valuation

See full

Market cap$890.32M+67.5%

Enterprise value$642.72M+37.0%

P/E7.8×—

P/S8.1×0.0×

Profitability

See full

Gross margin60.8%—

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

FCF margin221.9%+206pp

Returns & leverage

See full

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's SG&A?: Theravance Biopharma (TBPH) reported SG&A of $17.72M in Q1 2026.
How has Theravance Biopharma's SG&A changed year-over-year?: Theravance Biopharma's SG&A decreased by 3.5% year-over-year, from $18.37M to $17.72M.
What is the long-term trend for Theravance Biopharma's SG&A?: Over 4 years (2021 to 2025), Theravance Biopharma's SG&A has grown at a -7.2% compound annual growth rate (CAGR), from $99.3M to $73.65M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.